



Oregon Prescription Drug Affordability Board

350 Winter Street NE, Salem, OR 97309-0405 | 971-374-3724 | pdab@dcbs.oregon.gov | dfr.oregon.gov/pdab

Agenda

This is a regular meeting. *Date: July 16, 2025 | Time: 9 a.m.*

This is a draft agenda and subject to change

Board Members:

Chair Shelley Bailey
Vice Chair Dr. Amy Burns
Dr. Daniel Hartung
Dr. Christopher Laman
John Murray
Dan Kennedy
Lauri Hoagland

Meeting name

Prescription Drug Affordability Board

Meeting location

Virtual

Zoom link

[Register for meeting](#)

Staff: Cortnee Whitlock, senior policy analyst; Stephen Kooyman, project manager, Heather Doyle, data analyst; Pei-Chen Choo, research analyst; Melissa Stiles, administrative specialist; Pramela Reddi, counsel

Purpose	Subject	Presenter
<i>Informational and vote</i>	Call to order and roll call	Chair Shelley Bailey
<i>Informational</i>	Board declarations of conflict of interest and meetings with entities or individuals related to board activities	Chair Shelley Bailey
<i>Discussion and vote</i>	Board approval of 6/18/2025 minutes	Chair Shelley Bailey
<i>Informational</i>	PDAB program update	DCBS Staff
<i>Informational</i>	General public comment: limited to 3 minutes	Chair Shelley Bailey
<i>Discussion</i>	Board discussion about a process for measuring affordability to determine drug review cost impact	Chair Shelley Bailey, Cortnee Whitlock, senior policy analyst
<i>Review and discussion</i>	Drug review: Antipsychotics & Antimanic agents – Vraylar ¹	Cortnee Whitlock
<i>Review and discussion</i>	Drug review: Cardiovascular agents – Entresto ¹	Cortnee Whitlock
<i>Review and discussion</i>	Drug review: Migraine products – Ajovy ¹	Cortnee Whitlock

¹ The board is conducting drug reviews per ORS 646A.694 and OAR 925-200-0020. There will be a public comment period for the prescription drug selected for cost review. Each speaker will have 3 minutes. Board members may have follow-up questions for the speakers. The board chair has the discretion to extend a speaker's time. The board will hear from patients, caregivers, and individuals with scientific or medical background, per ORS 646A.694(3).

Purpose	Subject	Presenter
<i>Review and discussion</i>	Drug review: Migraine products – Emgality ¹	Cortnee Whitlock
<i>Review and discussion</i>	Drug review: Migraine products – Nurtec ¹	Cortnee Whitlock
<i>Review and discussion</i>	Drug review: Migraine products – Ubrelvy ¹	Cortnee Whitlock
<i>Break</i>	The board will take a break around 10:30	Chair Shelley Bailey
<i>Informational</i>	Announcements	Chair Shelley Bailey
<i>Vote</i>	Adjournment	Chair Shelley Bailey

Accessibility

Anyone needing assistance due to a disability or language barrier can contact Melissa Stiles at least 48 hours ahead of the meeting at pdab@dcbs.oregon.gov or 971-374-3724. American sign language will be available during the July 16 board meeting.

How to provide testimony to the board

The Prescription Drug Affordability Board invites people to provide testimony. **Oral:** To speak to the board during the public comment portion of the agenda, please submit the [PDAB public comment form](#) no later than 24 hours before the PDAB meeting. **Written:** to provide written comments to the board, please submit the [PDAB public comment form](#) with attachments no later than 48 hours before the PDAB meeting. The board reviews all written comments. All written comments are posted on the website.

Open and closed sessions

All board meetings except executive sessions are open to the public. Pursuant to ORS 192.660, executive sessions are closed to everyone but news media and staff. No action will be taken in executive session.

¹ The board is conducting drug reviews per ORS 646A.694 and OAR 925-200-0020. There will be a public comment period for the prescription drug selected for cost review. Each speaker will have 3 minutes. Board members may have follow-up questions for the speakers. The board chair has the discretion to extend a speaker's time. The board will hear from patients, caregivers, and individuals with scientific or medical background, per ORS 646A.694(3).